Interim-response-adapted therapy in advanced Hodgkin's lymphoma: Current status

摘要

It has been 6 years after our initial publication of a phase II trial of response-adapted therapy (RAT) in advanced Hodgkin's lymphoma (aHL), which was one of the first prospectivestudies published using RAT in aHL.[1] We had treated patients with aHL (defined as Stage IIB, III, and IV) with two cycles of ABVD and then performed an interim positron emissiontomography/computed tomography (iPET-CT) scan iPET2. Those who had a Deauville score (DS) of 4 or 5 received four cycles of escalated BEACOPP (EB) and those with DS 1–3continued 4 more ABVD. The disease-free survival (DFS) at 2 years was 76%, and overall survival (OS) was 88%. With more mature follow-up, the DFS at 5 years was 77%, and OSwas 85% for the entire cohort of 50 patients.[2] The survival was inferior among iPET2+ (5-year DFS [50%] and OS [62%]) versus iPET2-?ve patients (5-year DFS [82%] and OS [85%]).These results have been replicated in much larger multicenter studies globally, and RAT has been accepted as one of the standard modes of treatment in aHL.